Insider Trading Pulse — August 05, 2026

Founder & CEO Andrew Florance bought 83,300 shares at $29.89 for ~$2.49M, a massive open-market purchase signaling extreme confidence in the company's valuation and future prospects. This is the single most bullish signal of the day.

President Joel Bender sold 100,000 shares at $63.89 (~$6.39M) and EVP/CEO Stephen Tadlock sold 38,455 shares at $63.80 (~$2.45M). This combined ~$8.8M insider sell-off, even if plan-driven, represents a massive reduction in insider exposure and is a strong bearish signal for the energy services sector.

Director Jon Louis Girod bought 1,000 shares at $5.41 (~$5.4K), increasing his stake by 50%. This is a high-conviction insider buy at a low absolute price, suggesting the director sees significant upside from current levels.

Director Herbert Elmer Richerson bought 30 shares at $83.45 (~$2.5K). While a small absolute amount, it is a consistent vote of confidence from a long-tenured insider, adding to a positive signal for this regional bank.

Large shareholder Suzanne L. Helen sold 7,000 shares at $131.52 for ~$921K, reducing her position by nearly 50%. This significant sell-down by a major holder is a bearish signal for the flooring and building products sector.

President & CEO Marita Zuraitis sold 7,500 shares at $52.03 for ~$390K under a 10b5-1 plan. While plan-driven, the size of the sale is notable and could indicate a planned diversification at current price levels.

Chief Risk Officer Stephanie N. Richard sold 5,000 shares at $44.23 for ~$221K under a 10b5-1 plan. A notable sale from a key risk oversight executive, potentially signaling a cautious internal view on credit or market risk.

President and CEO Ram Aiyar sold 5,802 shares at $10.84 for ~$62.9K. A direct sale by the CEO of a pre-commercial biotech is a bearish signal, potentially indicating a lack of near-term confidence in the stock's trajectory.

Chief Scientific Officer Gwenn Hansen sold a total of 4,111 shares at ~$24.64 for ~$100K under a 10b5-1 plan. Consistent selling by a key scientific leader is a cautionary signal for this biotech.

See Remarks officer Dennis Cho sold 1,070 shares at $85.32 for ~$91.3K. A small but notable sale by an insider at a high stock price, potentially indicating profit-taking after a strong run.

President and EVP/CEO sold a combined ~$8.84M in stock. This massive insider liquidation, even if pre-planned, creates a significant overhang and signals a potential peak in insider confidence for the energy services company.

Large shareholder Suzanne L. Helen sold ~$921K worth of stock, reducing her holdings by ~50%. This aggressive sell-down by a major investor is a significant red flag for the company's near-term outlook.

CEO Marita Zuraitis sold $390K worth of stock. While a 10b5-1 plan provides cover, the initiation of a large sale plan by a CEO warrants close monitoring for any fundamental deterioration.

The Chief Risk Officer sold $221K in stock. Sales by risk officers can be a leading indicator of internal concerns about credit quality or market risk, especially in the current rate environment.

CEO Ram Aiyar sold $62.9K of stock directly. For a pre-revenue biotech, any insider sale by the CEO is a risk flag, as it contradicts the narrative of management's full commitment to the long-term thesis.

Chief Scientific Officer Gwenn Hansen sold ~$100K under a 10b5-1 plan. Consistent selling by a key scientific leader is a risk for a clinical-stage biotech where scientific execution is paramount.

Director Royce A. Wells sold 787 shares for ~$39.4K. While small, a direct sale by a director is a minor risk flag for this regional bank.

Officer Dennis Cho sold $91.3K in stock. While small, this sale at a high stock price could indicate that insiders believe the stock is fully valued.

Founder & CEO Andrew Florance's $2.49M open-market purchase is a powerful vote of confidence. This signals that the company's leadership believes the stock is significantly undervalued, presenting a potential buying opportunity for investors who share that view.

Director Jon Louis Girod increased his stake by 50% with a $5.4K purchase at $5.41. This insider buying at a low absolute price point suggests a potential value play or turnaround story in the regional banking sector.

Director Herbert Elmer Richerson's small but consistent purchase of 30 shares adds to a pattern of insider confidence. This signals a stable and potentially undervalued regional bank.

The Chairman & CEO was awarded 50,000 RSUs, and the President & COO was awarded 25,000 RSUs. This substantial equity grant aligns management with long-term shareholder value creation and suggests confidence in the company's future.

Three directors were each awarded 37,653 stock options. This is a strong incentive for these directors to drive significant share price appreciation, aligning their interests with shareholders.

Director Andrew Jon Cutler was awarded 472,222 stock options. This massive option grant creates a powerful incentive for the director to increase shareholder value, a positive signal for this micro-cap biotech.

CFO Mark Scheiwer and EVP Christopher Hagedorn both acquired shares at $56.55. While small amounts (~$150 and ~$217), these purchases by top finance and strategy executives signal a belief that the stock is at a reasonable entry point.

Interim CFO David Ross Smith was awarded 15,840 RSUs. This significant award provides strong retention and incentive for the interim CFO, ensuring stability during a leadership transition.

The massive insider sell-off at Cactus, Inc. (WHD) by its President and EVP/CEO, totaling ~$8.8M, suggests that insiders in the energy services sector are taking profits or hedging against a potential downturn. This is a strong contrarian signal to the sector's recent performance.

A cluster of insider selling at pre-commercial and clinical-stage biotechs (Korro Bio, Nurix Therapeutics) indicates a cautious internal view. CEO and CSO sales at these firms are particularly notable, suggesting management may lack confidence in near-term catalysts or valuation.

The day's filings show a clear divergence in regional bank insider sentiment. While Wilson Bank and Riverview Bancorp saw insider buying, Amalgamated Financial Corp saw a director sale. This suggests a stock-specific rather than sector-wide view among bank insiders.

The most powerful signal of the day is the contrast between CoStar Group's founder making a massive open-market purchase ($2.49M) and the top executives at Cactus, Inc. executing a massive sell-off ($8.8M). This highlights the importance of distinguishing between founder/owner-operator conviction and hired management diversification.

The vast majority of filings (over 40) are routine equity awards (RSUs, stock options) or small, often plan-driven, transactions. This creates a low-signal environment where the few high-conviction open-market purchases and large sales stand out even more. The key is to filter out the noise and focus on the outliers.

Monitor for any 8-K filings or investor presentations following the CEO's massive $2.49M purchase. The market's reaction to this signal and any subsequent commentary from management will be key.

Watch for any forward-looking guidance or operational updates following the ~$8.8M insider sell-off. The next earnings call will be critical to assess if the insider selling was a leading indicator of a slowdown.

Monitor for any filings or news that might explain the large shareholder's ~50% reduction in holdings. This could be a signal of broader sector weakness or company-specific issues.

The CEO's $390K 10b5-1 sale plan should be monitored. The next earnings report will be key to see if the sale was timed ahead of any negative news.

The CRO's $221K sale under a 10b5-1 plan warrants close monitoring of Ally's upcoming credit quality and loan loss provision data. Any deterioration would validate the risk officer's apparent caution.

The director's 50% stake increase at $5.41 makes this a key stock to watch for a potential turnaround or value realization event in the regional banking space.

Monitor for any clinical data readouts or partnership announcements. The CEO and CSO sales at these biotechs make upcoming catalysts even more critical for the stock's direction.